Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

This randomized phase III trial studies antiemetic therapy with olanzapine to see how well
they work compared to antiemetic therapy alone in preventing chemotherapy-induced nausea and
vomiting in patients with cancer receiving highly emetogenic (causes vomiting) chemotherapy.
Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron
hydrochloride, may help lessen or prevent nausea and vomiting in patients treated with
chemotherapy. Olanzapine may help prevent chemotherapy-induced nausea and vomiting by
blocking brain receptors that appear to be involved in nausea and vomiting.

Intervention

Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo

Condition

Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific

Investigators

See list of participating sites